Free Biopharma Daily Stock Updates - 11/17/21

$XBI $122.93 -1.27%

---

Covid Updates

$NVAX +7.9% Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization. source

$NVAX +7.9% Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines. source

$MRNA +3.4% Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years. source

$ZSAN +10.2% Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System. source

Pipeline Updates

$ARWR -0.3% Arrowhead Announces JNJ-75220795 in Development for NASH. source

$LNTH -0.8% Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings. source

$DRMA -1.2% Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea. source

$GRPH -0.30% Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease. source

$MRTX -2.4% Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers. source

$ABEO -2.4% Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference. source

$ELOX -26.4% Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients. source

$ZNTL +2.9% Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma. source

Business Updates

$CBAY -4.7% CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants source

---

Posted by FS/JM